NCT03957694View on ClinicalTrials.gov

Study of AMG531(Romiplostim) in Patients With Aplastic Anemia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 25, 2019

Primary Completion Date

November 5, 2020

Study Completion Date

May 26, 2021

Conditions
Aplastic Anemia
Interventions
DRUG

Romiplostim

Romiplostim SC. Initial dose is 10 ug/kg/. Maximum dose is 20 ug/kg. Original duration is 6 months from first administration but if investigator decide that the patient is needed more treatment, they move to extention period and take treatment up to 1 year.

Trial Locations (1)

Unknown

Matsuyama Red Cross Hospital, Ehime

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT03957694 - Study of AMG531(Romiplostim) in Patients With Aplastic Anemia | Biotech Hunter | Biotech Hunter